<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031153</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study).</ArticleTitle><Pagination><StartPage>1565094</StartPage><MedlinePgn>1565094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1565094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1565094</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Patients receiving anticoagulation for atrial fibrillation (AF) are required to consult their doctor before starting Ramadan fasting to get their authorization for fasting and adapt their treatment. More often, a once-daily regimen is proposed to facilitate their intake schedule. Apixaban, a direct oral anticoagulant, prescribed twice daily with an optimal benefit/risk ratio in numerous situations, has very limited data regarding its use during Ramadan.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">The aim of this study was to evaluate the safety and the efficacy of apixaban for stroke prevention in AF patients during the month of Ramadan.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">An observational, multicentric study was performed in Tunisia during two consecutive years during the specific month of Ramadan. The API-RAM study included AF patients who were on apixaban and fasted at least 10&#xa0;days. Efficacy was defined by the absence of ischemic events, and safety was established by classifying bleeding events using the BARC (Bleeding Academic Research Consortium) classification during the study period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 257 patients were included in our study. No ischemic events were reported during the study period. Minor bleeding events were reported in only 12 patients (4.7%), with no major bleeding event. Based on multivariate analysis, independent predictors for the bleeding risk of our population were as follows: smoking, history of hypertension, and creatinine clearance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Apixaban seems to be safe and effective for the prevention of the thromboembolic episode in AF patients during Ramadan fasting. Larger studies such as randomized clinical trials are necessary to confirm these results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Ghrab, Gargouri, Addad, Cheikhrouhou, Jabeur, Charfeddine, Bahloul, Triki, Ellouze, Abidi, Mallek, Triki, Abdessalem, Elalamy and Abid.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghrab</LastName><ForeName>Aiman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargouri</LastName><ForeName>Rania</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addad</LastName><ForeName>Faouzi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheikhrouhou</LastName><ForeName>Anis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabeur</LastName><ForeName>Mariem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charfeddine</LastName><ForeName>Selma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahloul</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Zied</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellouze</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abidi</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hannibal Clinic, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallek</LastName><ForeName>Souad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triki</LastName><ForeName>Faten</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdessalem</LastName><ForeName>Salem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic Pasteur Tunis, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elalamy</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Department, American Hospital of Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondation UPM des Sciences de la Sant&#xe9;, Marrakesh, Morocco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abid</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Department, Hedi Chaker University Hospital Sfax, Sfax, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ramadan</Keyword><Keyword MajorTopicYN="N">anticoagulants</Keyword><Keyword MajorTopicYN="N">apixaban</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">fasting</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031153</ArticleId><ArticleId IdType="pmc">PMC12476992</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1565094</ArticleId><ArticleId IdType="pii">1565094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addad F., Amami M., Ibn Elhadj Z., Chakroun T., Marrakchi S., Kachboura S. (2014). Does ramadan fasting affect the intensity of acenocoumarol-induced anticoagulant effect? Br. J. Haematol. 166 (5), 792&#x2013;794. 10.1111/bjh.12897</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12897</ArticleId><ArticleId IdType="pubmed">24749553</ArticleId></ArticleIdList></Reference><Reference><Citation>
Agrawal A., Kerndt C. C., Manna B. (2024). &#x201c;Apixaban,&#x201d; in 
<i>StatPearls. Treasure Island</i>
, FL: StatPearls Publishing. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK507910/(Accessed: January 4, 2025).</Citation></Reference><Reference><Citation>Akhtar A. M., Ghouri N., Chahal C. A. A., Patel R., Ricci F., Sattar N., et al. (2022). Ramadan fasting: recommendations for patients with cardiovascular disease. Heart 108 (4), 258&#x2013;265. 10.1136/heartjnl-2021-319273</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319273</ArticleId><ArticleId IdType="pmc">PMC8819657</ArticleId><ArticleId IdType="pubmed">33990414</ArticleId></ArticleIdList></Reference><Reference><Citation>AlAyoubi F. (2021). The effect of ramadan fasting on oral anticoagulant: experience of tertiary academic hospital. Ann. Rev. and Res. 6 (3). 10.19080/ARR.2021.06.555688</Citation><ArticleIdList><ArticleId IdType="doi">10.19080/ARR.2021.06.555688</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ghumlas A. K. (2024). Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case&#x2013;control study. Sci. Rep. 14 (1), 13855. 10.1038/s41598-024-64582-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-64582-8</ArticleId><ArticleId IdType="pmc">PMC11180170</ArticleId><ArticleId IdType="pubmed">38879576</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulhem M., Susarla R., Alabdulaali L., Khunti K., Karamat M. A., Rasiah T., et al. (2020). The effect of ramadan fasting on cardiovascular events and risk factors in patients with type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 159, 107918. 10.1016/j.diabres.2019.107918</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2019.107918</ArticleId><ArticleId IdType="pubmed">31711857</ArticleId></ArticleIdList></Reference><Reference><Citation>AlShoaibi N., Al Harbi M., Modaimegh H., Al Qubbany A., Al Saif S., Connolly D. L., et al. (2021). Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: perspectives on improving patient care. Expert Rev. Cardiovasc. Ther. 19 (3), 221&#x2013;236. 10.1080/14779072.2021.1878878</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14779072.2021.1878878</ArticleId><ArticleId IdType="pubmed">33475462</ArticleId></ArticleIdList></Reference><Reference><Citation>Anghel L. A., Farcas A. M., Oprean R. N. (2019). An overview of the common methods used to measure treatment adherence. Med. Pharm. Rep. 92 (2), 117&#x2013;122. 10.15386/mpr-1201</Citation><ArticleIdList><ArticleId IdType="doi">10.15386/mpr-1201</ArticleId><ArticleId IdType="pmc">PMC6510353</ArticleId><ArticleId IdType="pubmed">31086837</ArticleId></ArticleIdList></Reference><Reference><Citation>Batarfi A., Alenezi H., Alshehri A., Balelah S., Kazim H., Algthami M., et al. (2021). Patient-guided modifications of oral anticoagulant drug intake during ramadan fasting: a multicenter cross-sectional study. J. Thrombosis Thrombolysis 51 (2), 485&#x2013;493. 10.1007/s11239-020-02218-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02218-0</ArticleId><ArticleId IdType="pmc">PMC7886720</ArticleId><ArticleId IdType="pubmed">32666427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortman L. V., Mitchell F., Naveiro S., P&#xe9;rez Morales J., Gonzalez C. D., Di Girolamo G., et al. (2023). Direct oral anticoagulants: an updated systematic review of their clinical pharmacology and clinical effectiveness and safety in patients with nonvalvular atrial fibrillation. J. Clin. Pharmacol. 63 (4), 383&#x2013;396. 10.1002/jcph.2184</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.2184</ArticleId><ArticleId IdType="pubmed">36433678</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajos G., Konieczynska M., Zalewski J., Undas A. (2015). Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc. Diabetol. 14, 44. 10.1186/s12933-015-0207-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-015-0207-2</ArticleId><ArticleId IdType="pmc">PMC4432887</ArticleId><ArticleId IdType="pubmed">25928628</ArticleId></ArticleIdList></Reference><Reference><Citation>
Granger C. B., Alexander J. H., McMurray J. J. V., Lopes R. D., Hylek E. M., Hanna M., et al.  (2011). Apixaban <i>versus</i> warfarin in patients with atrial fibrillation. N. Engl. J. Med.
365 (11), 981&#x2013;992. 10.1056/NEJMoa1107039

</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Harskamp R. E., Lucassen W. A. M., Lopes R. D., Himmelreich J. C. L., Parati G., Weert H. C. P. M. v. (2022). Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 77 (3), 191&#x2013;195. 10.1080/00015385.2021.1882111</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00015385.2021.1882111</ArticleId><ArticleId IdType="pubmed">33685380</ArticleId></ArticleIdList></Reference><Reference><Citation>Katada Y., Nakagawa S., Nishimura A., Sato Y. K., Taue H., Matsumura K., et al. (2019). Effects of fasting on warfarin sensitivity index in patients undergoing cardiovascular surgery. Eur. J. Clin. Pharmacol. 75 (4), 561&#x2013;568. 10.1007/s00228-018-2592-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-018-2592-4</ArticleId><ArticleId IdType="pubmed">30460405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B. H., Joo Y., Kim M. S., Choe H. K., Tong Q., Kwon O. (2021). Effects of intermittent fasting on the circulating levels and circadian rhythms of hormones. Endocrinol. Metabolism 36 (4), 745&#x2013;756. 10.3803/EnM.2021.405</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2021.405</ArticleId><ArticleId IdType="pmc">PMC8419605</ArticleId><ArticleId IdType="pubmed">34474513</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsted A., Nordestgaard B. G. (2018). Smoking is associated with increased risk of major bleeding: a prospective cohort study. Thrombosis Haemostasis 119, 39&#x2013;47. 10.1055/s-0038-1675798</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1675798</ArticleId><ArticleId IdType="pubmed">30597498</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R., Rao S. V., Bhatt D. L., Gibson C. M., Caixeta A., Eikelboom J., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (23), 2736&#x2013;2747. 10.1161/CIRCULATIONAHA.110.009449</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.009449</ArticleId><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirghani H. O., Faisal A. F. F., Salman A. W., Hussain G. A., Abdulaziz A. E., Muflih A. M., et al. (2023). Adherence to antidiabetic medication during the month of ramadan among diabetes mellitus patients in the Kingdom of Saudi Arabia. J. Adv. Zoology 44 (5), 747&#x2013;755. 10.53555/jaz.v44i5.3110</Citation><ArticleIdList><ArticleId IdType="doi">10.53555/jaz.v44i5.3110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali S., Ben Halima A., Chabrak S., Chettaoui R., Ben Halima M., Haggui A., et al. (2021). Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: results from the national Tunisian registry of atrial fibrillation (NATURE&#x2010;AF). Clin. Cardiol. 44 (4), 501&#x2013;510. 10.1002/clc.23558</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23558</ArticleId><ArticleId IdType="pmc">PMC8027580</ArticleId><ArticleId IdType="pubmed">33704830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;aloza-Mart&#xed;nez E., Moreno G., Aroca-Crevill&#xe9;n A., Huertas S., Vicent L., Rosillo N., et al. (2022). Circadian rhythms in thrombosis and atherothrombotic events. Front. Bioscience-Landmark 27 (2), 51. 10.31083/j.fbl2702051</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbl2702051</ArticleId><ArticleId IdType="pubmed">35226994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad M. S. (2023). Ramadan fasting as a goal-pursuit: why people fast, and how motives affect their experience. Motivation Sci. 9, 327&#x2013;339. 10.1037/mot0000310</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/mot0000310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosca C. I., Sharma A., Nisulescu D. D., Otiman G., Duda-Seiman D. M., Morariu S. I., et al. (2023). Prevalence of cardio-embolic brain complications in permanent and paroxysmal atrial fibrillation patients. Healthcare 11 (2), 175. 10.3390/healthcare11020175</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11020175</ArticleId><ArticleId IdType="pmc">PMC9858915</ArticleId><ArticleId IdType="pubmed">36673543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandrini L., Ieraci A., Amadio P., Zar&#xe0; M., Barbieri S. S. (2020). Impact of acute and chronic stress on thrombosis in healthy individuals and cardiovascular disease patients. Int. J. Mol. Sci. 21 (21), 7818. 10.3390/ijms21217818</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21217818</ArticleId><ArticleId IdType="pmc">PMC7659944</ArticleId><ArticleId IdType="pubmed">33105629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoeb M., Fang M. C. (2013). Assessing bleeding risk in patients taking anticoagulants. J. thrombosis thrombolysis 35 (3), 312&#x2013;319. 10.1007/s11239-013-0899-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-013-0899-7</ArticleId><ArticleId IdType="pmc">PMC3888359</ArticleId><ArticleId IdType="pubmed">23479259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan K., Al Banna R., Qader A. M., Husain A. (2021). Does fasting during ramadan influence the therapeutic effect of warfarin? J. Clin. Pharm. Ther. 46 (1), 86&#x2013;92. 10.1111/jcpt.13254</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13254</ArticleId><ArticleId IdType="pubmed">32926452</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabelsi K., Ammar A., Boujelbane M. A., Puce L., Garbarino S., Scoditti E., et al. (2022). Religious fasting and its impacts on individual, public, and planetary health: fasting as a &#x201c;religious health asset&#x201d; for a healthier, more equitable, and sustainable society. Front. Nutr. 9, 1036496. 10.3389/fnut.2022.1036496</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.1036496</ArticleId><ArticleId IdType="pmc">PMC9729557</ArticleId><ArticleId IdType="pubmed">36505246</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijens B., Heidbuchel H. (2015). Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. EP Eur. 17 (4), 514&#x2013;523. 10.1093/europace/euu311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu311</ArticleId><ArticleId IdType="pubmed">25694538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Chang A. R., Inker L. A., McAdams-DeMarco M., Grams M. E., Shin J. I. (2023). Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease. Circulation 148 (19), 1445&#x2013;1454. 10.1161/CIRCULATIONAHA.123.065614</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.065614</ArticleId><ArticleId IdType="pmc">PMC10840683</ArticleId><ArticleId IdType="pubmed">37681341</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz T. (2023). Evaluation of medication adherence of individuals with chronic diseases during ramadan. Ankara Med. J. 23 (3), 344&#x2013;356. 10.5505/amj.2023.70842</Citation><ArticleIdList><ArticleId IdType="doi">10.5505/amj.2023.70842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zghal Mghaieth F., Bonkano A., Boudiche S., Ayari J., Ben Mansour N., Rekik B., et al. (2019). Oral anticoagulation therapy using acenocoumarol during the month of ramadan: a comparative study between fasting and non-fasting patients. La Tunis. Medicale 97 (10), 1177&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691946</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41025486</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Trimetazidine Is Associated With Ameliorated Stroke Risk in Patients With Both Ischemic Heart Disease and Atrial Fibrillation.</ArticleTitle><Pagination><StartPage>e041629</StartPage><MedlinePgn>e041629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.125.041629</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myocardial ischemia is closely associated with arrhythmogenesis and prognostication in patients with atrial fibrillation (AF). Trimetazidine ameliorates myocardial ischemia through prioritizing cardiomyocyte metabolism to glucose oxidation. Whether trimetazidine clinically reduces stroke risk in patients with ischemic heart disease and AF was unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited patients with ischemic heart disease from the Hong Kong Clinical Data Analysis and Reporting System between January 1, 1999 and December 31, 2020. Patients with comorbid AF were identified, and those with a history of prior stroke were excluded. Trimetazidine users and nonusers (with long-acting nitrates as the control) were compared for the primary end point of incident ischemic stroke using Cox proportional regression, with and without propensity matching.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary analysis included 12&#x2009;527 patients with ischemic heart disease and preexisting AF (mean age, 77.5&#xb1;10.3&#x2009;years; 44.6% men), who were further categorized as trimetazidine users (n=960) versus nonusers (n=11&#x2009;567). Over a follow-up period of 1133 (interquartile range, 442-2454) days, 2160 patients (17.2%) developed new-onset ischemic stroke. Trimetazidine use was independently associated with a lower risk of new-onset ischemic stroke (hazard ratio [HR], 0.55 [95% CI, 0.44-0.68]; <i>P</i>&lt;0.001). Propensity score-matched analyses revealed similar findings (adjusted HR, 0.65 [95% CI, 0.52-0.80]; <i>P</i>&lt;0.001). Furthermore, trimetazidine was also independently associated with a lower risk of recurrent ischemic stroke (HR, 0.51 [95% CI, 0.37-0.69]; <i>P</i>&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with trimetazidine is associated with a lower risk of incident and recurrent stroke in patients with both ischemic heart disease and AF. These findings will need to be confirmed in randomized controlled trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yuen-Ting</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0002-8277-5218</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lip</LastName><ForeName>Gregory Y H</ForeName><Initials>GYH</Initials><Identifier Source="ORCID">0000-0002-7566-1626</Identifier><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science at University of Liverpool Liverpool John Moores University and Liverpool Heart and Chest Hospital Liverpool UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine Aalborg University Aalborg Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Bernard M Y</ForeName><Initials>BMY</Initials><Identifier Source="ORCID">0000-0001-9106-7363</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yiu</LastName><ForeName>Kai-Hang</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0003-2145-3108</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Shenzhen Hong Kong University Hospital Shenzhen China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science and Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Hung-Fat</ForeName><Initials>HF</Initials><Identifier Source="ORCID">0000-0002-9578-7808</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Shenzhen Hong Kong University Hospital Shenzhen China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Research Program for Personalized Medicine in Cardiac Oncology The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Yap-Hang</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0001-5384-8468</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Science and Medicine The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Research Program for Personalized Medicine in Cardiac Oncology The University of Hong Kong Hong Kong SAR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine and Immunotherapeutics Cambridge University Hospitals NHS Foundation Trust/University of Cambridge Cambridge UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology Royal Papworth Hospital, Cambridge Biomedical Campus Cambridge UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">ischemia</Keyword><Keyword MajorTopicYN="N">metabolic reprogramming</Keyword><Keyword MajorTopicYN="N">stroke</Keyword><Keyword MajorTopicYN="N">trimetazidine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41025486</ArticleId><ArticleId IdType="doi">10.1161/JAHA.125.041629</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41020767</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0756</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Postgraduate medical journal</Title><ISOAbbreviation>Postgrad Med J</ISOAbbreviation></Journal><ArticleTitle>Association between rivaroxaban and the prognosis of patients with acute myocardial infarction and new-onset atrial fibrillation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">qgaf163</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/postmj/qgaf163</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">New-onset atrial fibrillation (AF) in the setting of acute myocardial infarction (AMI) is associated with higher risks of stroke and mortality. However, current guidelines lack specific antithrombotic recommendations for this population. This study aimed to explore the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study included patients with AMI and new-onset AF receiving dual antiplatelet therapy between August 2016 and June 2023 in Tianjin, China. New-onset AF (transient or nontransient) was defined as the first diagnosis of AF following AMI. The primary outcome was stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">2477 patients were identified, including 141 rivaroxaban users and 2336 patients without oral anticoagulants (OAC). Over a median follow-up of 922 days, rivaroxaban users had a 5.7% lower risk of stroke than non-OAC users, although this was not statistically significant (19.9% vs. 25.6%; P&#x2009;=&#x2009;.152). Despite the suggestion of a protective trend, multivariable Cox regression showed that rivaroxaban use was not associated with a lower risk of stroke (hazard ratio, 0.77; 95% confidence interval, 0.52-1.13, P&#x2009;=&#x2009;.187). After propensity score matching, 155 transient (rivaroxaban: 42; non-OAC: 113) and 295 nontransient AF patients (rivaroxaban: 85; non-OAC: 210) were included. No significant association was observed between rivaroxaban and stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">No significant association was observed between rivaroxaban and clinical outcomes in patients with AMI and new-onset AF. Given the small sample size and limited statistical power, the findings are exploratory and require further validation. Key messages &#x2002;What is already known on this topic: Evidence from previous studies indicates that acute myocardial infarction (AMI) patients with new-onset atrial fibrillation (AF) are associated with higher risks of ischemic stroke and mortality. However, the association between rivaroxaban and the prognosis of patients with AMI and new-onset AF remains uncertain. &#x2002;What this study adds: Among patients with AMI and new-onset AF receiving dual antiplatelet therapy, no significant differences were observed between rivaroxaban users and non-oral anticoagulant users in terms of the risks of stroke, ischemic stroke, hemorrhagic stroke, all-cause mortality, cardiovascular mortality, bleeding, or major bleeding. However, these results should be interpreted with caution due to the small sample size and limited statistical power of the study. &#x2002;How this study might affect research, practice or policy: Future prospective large-scale studies and randomized controlled trials are needed to further examine the role of rivaroxaban and other types of oral anticoagulants in patients with AMI and new-onset AF.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the Fellowship of Postgraduate Medicine. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Gary</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5510-1253</Identifier><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing and Health Sciences, Hong Kong Metropolitan University, 1 Sheung Shing Street, Quarry Hill, Kowloon, 999077, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lip</LastName><ForeName>Gregory Y H</ForeName><Initials>GYH</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart &amp; Chest Hospital, 6 West Derby Street, L7 8TX, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 7K, 9220, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kang-Yin</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Tong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0482-0738</Identifier><AffiliationInfo><Affiliation>Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TJWJ2022XK013</GrantID><Agency>Construction Project</Agency><Country/></Grant><Grant><GrantID>TJYXZDXK-029A</GrantID><Agency>Tianjin Key Medical Discipline</Agency><Country/></Grant><Grant><GrantID>82170327</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82370332</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Postgrad Med J</MedlineTA><NlmUniqueID>0234135</NlmUniqueID><ISSNLinking>0032-5473</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute myocardial infraction</Keyword><Keyword MajorTopicYN="N">bleeding</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">new-onset atrial fibrillation</Keyword><Keyword MajorTopicYN="N">rivaroxaban</Keyword><Keyword MajorTopicYN="N">stroke</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41020767</ArticleId><ArticleId IdType="doi">10.1093/postmj/qgaf163</ArticleId><ArticleId IdType="pii">8267895</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41010984</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Atrial Fibrillation Predictors in ECG After Mitral Valve Repair Surgery in Patients with Mitral Valve Prolapse.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1593</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina61091593</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: Atrial fibrillation (AF) is a common arrhythmia in patients with mitral valve prolapse (MVP) after mitral valve repair surgery and is associated with adverse cardiac outcomes. Early identification of patients at high risk for AF development after repair surgery is crucial for early treatment and follow-up of these patients. This study aimed to identify ECG predictors of AF in patients with MVP following mitral valve repair surgery. <i>Materials and Methods</i>: This retrospective, non-randomized study included 62 patients who underwent mitral valve repair for MVP. The patients' ECGs were analyzed preoperatively and at 1, 3, and 6 months post-surgery to identify patients who developed AF. AF was diagnosed based on ECG findings or Holter monitoring. The P wave dispersion, P wave peak time (PWPT), P wave duration, PR interval, P wave terminal force in lead V1 (PWTF), interatrial block, P wave axis, biphasic P waves in inferior leads, QRS duration, corrected QT interval (QTc), fragmented QRS (fQRS), and ST segment-T wave abnormalities were analyzed on baseline ECG as AF predictors. <i>Results</i>: The PWPT, P wave dispersion, and maximum P wave duration were significantly longer on preoperative ECG in patients who developed AF postoperatively compared to those who did not. Biphasic P waves were more frequently observed in patients who developed AF postoperatively. Univariate analysis identified biphasic P waves, P wave dispersion, maximum P wave duration, PWPT, and left ventricular ejection fraction (LVEF) as potential predictors of postoperative AF. However, multivariate analysis revealed that P wave dispersion, PWPT, and left atrial volume index (LAVI) were independent predictors of AF in six months after mitral valve repair. No significant changes were observed in QRS duration, QT interval, or the fQRS. <i>Conclusions</i>: The P wave dispersion, PWPT, and LAVI are significant ECG predictors of AF following mitral valve repair surgery in MVP patients. These ECG markers may help identify individuals at higher risk for postoperative AF, allowing for targeted monitoring and management strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akhundova</LastName><ForeName>Aysel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Istanbul Medipol University, 34214 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savur</LastName><ForeName>Umeyir</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1320-9033</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Istanbul Medipol University, 34214 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakgor</LastName><ForeName>Aykun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8252-0373</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Istanbul Medipol University, 34214 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arman</LastName><ForeName>Mehmet Emir</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-4045-4969</Identifier><AffiliationInfo><Affiliation>Internal Medicine, Ascension St. Vincent Hospital-Indianapolis, Indianapolis, IN 46260, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boztosun</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Faculty of Medicine, Istanbul Medipol University, 34214 Istanbul, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008945" MajorTopicYN="Y">Mitral Valve Prolapse</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="Y">Electrocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008943" MajorTopicYN="N">Mitral Valve</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECG parameters</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">left atrium</Keyword><Keyword MajorTopicYN="N">mitral valve prolapse</Keyword><Keyword MajorTopicYN="N">mitral valve repair</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41010984</ArticleId><ArticleId IdType="pmc">PMC12471886</ArticleId><ArticleId IdType="doi">10.3390/medicina61091593</ArticleId><ArticleId IdType="pii">medicina61091593</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Battaglia V., Santangelo G., Bursi F., Simeoli P., Guazzi M. Arrhythmogenic Mitral Valve Prolapse and Sudden Cardiac Death: An Update and Current Perspectives. Curr. Probl. Cardiol. 2023;48:101724. doi: 10.1016/j.cpcardiol.2023.101724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2023.101724</ArticleId><ArticleId IdType="pubmed">36967070</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone A., D&#x2019;Andrea A., Scognamiglio G., Scarafile R., Tocci G., Sperlongano S., Martone F., Radmilovic J., D&#x2019;Amato M., Liccardo B., et al. Mitral Prolapse: An Old Mysterious Entity&#x2014;The Incremental Role of Multimodality Imaging in Sports Eligibility. J. Cardiovasc. Echogr. 2018;28:207&#x2013;217. doi: 10.4103/jcecho.jcecho_42_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jcecho.jcecho_42_18</ArticleId><ArticleId IdType="pmc">PMC6341849</ArticleId><ArticleId IdType="pubmed">30746324</ArticleId></ArticleIdList></Reference><Reference><Citation>Borger M.A., Mansour M.C., Levine R.A. Atrial Fibrillation and Mitral Valve Prolapse: Time to Intervene? J. Am. Coll. Cardiol. 2019;73:275&#x2013;277. doi: 10.1016/j.jacc.2018.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.11.018</ArticleId><ArticleId IdType="pmc">PMC6581561</ArticleId><ArticleId IdType="pubmed">30678756</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinding N.E., Kristensen S.L., R&#xf8;rth R., Butt J.H., &#xd8;stergaard L., Olesen J.B., Torp-Pedersen C., Gislason G.H., K&#xf8;ber L., Kruuse C., et al. Ischemic Stroke Severity and Mortality in Patients with and Without Atrial Fibrillation. J. Am. Heart Assoc. 2022;11:e022638. doi: 10.1161/JAHA.121.022638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.022638</ArticleId><ArticleId IdType="pmc">PMC9245802</ArticleId><ArticleId IdType="pubmed">35156393</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A., Beyersdorf F., Praz F., Milojevic M., Baldus S., Bauersachs J., Capodanno D., Conradi L., De Bonis M., De Paulis R., et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur. Heart J. 2022;43:561&#x2013;632. doi: 10.1093/eurheartj/ehab395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretto G., Durante A., Limite L.R., Cianflone D. Postoperative Arrhythmias after Cardiac Surgery: Incidence, Risk Factors, and Therapeutic Management. Cardiol. Res. Pract. 2014;2014:615987. doi: 10.1155/2014/615987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/615987</ArticleId><ArticleId IdType="pmc">PMC3912619</ArticleId><ArticleId IdType="pubmed">24511410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngaage D.L., Schaff H.V., Mullany C.J., Barnes S., Dearani J.A., Daly R.C., Orszulak T.A., Sundt T.M., III Influence of Preoperative Atrial Fibrillation on Late Results of Mitral Repair: Is Concomitant Ablation Justified? Ann. Thorac. Surg. 2007;84:434&#x2013;443. doi: 10.1016/j.athoracsur.2007.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2007.04.036</ArticleId><ArticleId IdType="pubmed">17643612</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal P., Kim M., Krishnan U., Mccullough S.A., Cheung J.W., Kim L.K., Pandey A., Borlaug B.A., Horn E.M., Safford M.M., et al. Post-operative atrial fibrillation and risk of heart failure hospitalization. Eur. Heart J. 2022;43:2971&#x2013;2980. doi: 10.1093/eurheartj/ehac285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac285</ArticleId><ArticleId IdType="pmc">PMC9890619</ArticleId><ArticleId IdType="pubmed">35764099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen H.J., Bohne L.J., Gillis A.M., Rose R.A. Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease. Heart Rhythm O2. 2020;1:147&#x2013;159. doi: 10.1016/j.hroo.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hroo.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC8183954</ArticleId><ArticleId IdType="pubmed">34113869</ArticleId></ArticleIdList></Reference><Reference><Citation>Albabtain M.A., Almathami E.A., Alghosoon H., Alsubaie F.F., Abdelaal I.M., Ismail H., Adam A.I., Arafat A.A. Scores predicting atrial fibrillation after mitral valve surgery: Do we need a more specific score? J. Arrhythmia. 2024;40:342&#x2013;348. doi: 10.1002/joa3.13002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/joa3.13002</ArticleId><ArticleId IdType="pmc">PMC10995589</ArticleId><ArticleId IdType="pubmed">38586847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneha K., Saha K.K., Mandal S., Sahoo S.S., Kumar V., Kumar M., Kumari S. Role of beta-blockers in reducing post-operative atrial fibrillation following cardiac surgery. Bioinformation. 2025;21:774&#x2013;782. doi: 10.6026/973206300210774.</Citation><ArticleIdList><ArticleId IdType="doi">10.6026/973206300210774</ArticleId><ArticleId IdType="pmc">PMC12236540</ArticleId><ArticleId IdType="pubmed">40636163</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein S.A., Green J., Huber K., Wojdyla D.M., Lopes R.D., Alexander J.H., Vinereanu D., Wallentin L., Granger C.B., Al-Khati S.M. Characteristics and outcomes of atrial fibrillation in patients with thyroid disease (from the ARISTOTLE trial) Am. J. Cardiol. 2019;124:1406&#x2013;1412. doi: 10.1016/j.amjcard.2019.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.07.046</ArticleId><ArticleId IdType="pmc">PMC7194994</ArticleId><ArticleId IdType="pubmed">31474328</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavares L., Lador A., Valderr&#xe1;bano M. Sleep Apnea and Atrial Fibrillation: Role of the Cardiac Autonomic Nervous System. Methodist Debakey Cardiovasc. J. 2021;17:49&#x2013;52. doi: 10.14797/ZYUT2951.</Citation><ArticleIdList><ArticleId IdType="doi">10.14797/ZYUT2951</ArticleId><ArticleId IdType="pmc">PMC8158444</ArticleId><ArticleId IdType="pubmed">34104320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani M.V., Pierucci N., Piro A., Trivigno S., Chimenti C., Galardo G., Miraldi F., Vizza C.D. Incidence and Determinants of Spontaneous Cardioversion of Early Onset Symptomatic Atrial Fibrillation. Medicina. 2022;58:1513. doi: 10.3390/medicina58111513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58111513</ArticleId><ArticleId IdType="pmc">PMC9693621</ArticleId><ArticleId IdType="pubmed">36363470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousou P.A., Chattopadhyay R., Tsampasian V., Vassiliou V.S., Pugh P.J. Review Electrocardiographic Predictors of Atrial Fibrillation. Med. Sci. 2023;11:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123668</ArticleId><ArticleId IdType="pubmed">37092499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell C., Rahko P.S., Blauwet L.A., Canaday B., Finstuen J.A., Foster M.C., Horton K., Ogunyankin K.O., Palma R.A., Velazquez E.J. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: The American Society of Echocardiography recommendations. J. Am. Soc. Echocardiogr. 2019;32:1&#x2013;64. doi: 10.1016/j.echo.2018.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.echo.2018.06.004</ArticleId><ArticleId IdType="pubmed">30282592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeis S., Gerstenfeld E.P., Kalman J., Saad E.B., Shamloo A.S., Andrade J.G., Barbhaiya C.R., Baykaner T., Boveda S., Calkins H., et al. 2024 European Heart Rhythm Association/ Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. EP Eur. 2024;26:euae043. doi: 10.1093/europace/euae043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euae043</ArticleId><ArticleId IdType="pubmed">38597857</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Riera A.R., de Abreu L.C., Barbosa-Barros R., Grindler J., Fernandes-Cardoso A., Baranchuk A. P-wave dispersion: An update. Indian Pacing Electrophysiol. J. 2016;16:126&#x2013;133. doi: 10.1016/j.ipej.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ipej.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5197451</ArticleId><ArticleId IdType="pubmed">27924760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges M.S., Salerno D.E.D. Bazett&#x2019;s qt correction reviewed: Evidence that a linear qt correction for heart rate is better. J. Am. Coll. Cardiol. 1983;1:694.</Citation></Reference><Reference><Citation>Mihos C.G., Santana O., Lamas G.A., Lamelas J. Incidence of postoperative atrial fibrillation in patients undergoing minimally invasive versus median sternotomy valve surgery. J. Thorac. Cardiovasc. Surg. 2013;146:1436&#x2013;1441. doi: 10.1016/j.jtcvs.2012.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2012.09.009</ArticleId><ArticleId IdType="pubmed">23040194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakkar M., Ascione R., James A.F., Angelini G.D., Suleiman M.S. Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery. Pharmacol. Ther. 2015;154:13&#x2013;20. doi: 10.1016/j.pharmthera.2015.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2015.06.009</ArticleId><ArticleId IdType="pubmed">26116810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilja M., Leaback R., Banefelt J., Park T.J., Shah D., Ferguson W.G., Friberg &#xd6;. Postoperative atrial fibrillation is associated with long-term morbidity and mortality in older adults: Analysis from the SWEDEHEART Registry. JTCVS Open. 2024;19:116&#x2013;130. doi: 10.1016/j.xjon.2024.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xjon.2024.03.001</ArticleId><ArticleId IdType="pmc">PMC11247231</ArticleId><ArticleId IdType="pubmed">39015455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim K.S., Kheirallah K.A., Megdadi M.A. Enlargement of the Left Atrium Strongly Predicts Postoperative Mortality Following Heart Valve Surgery. Vasc. Health Risk Manag. 2022;18:783&#x2013;791. doi: 10.2147/VHRM.S380463.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S380463</ArticleId><ArticleId IdType="pmc">PMC9532254</ArticleId><ArticleId IdType="pubmed">36212553</ArticleId></ArticleIdList></Reference><Reference><Citation>Stassen J., van Wijngaarden A.L., Wu H.W., Palmen M., Tomsic A., Delgado V., Bax J.J., Marsan N.A. Left atrial remodeling after mitral valve repair for primary mitral regurgitation: Evolution over time and prognostic significance. J. Cardiovasc. Dev. Dis. 2022;9:230. doi: 10.3390/jcdd9070230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd9070230</ArticleId><ArticleId IdType="pmc">PMC9320730</ArticleId><ArticleId IdType="pubmed">35877592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kizilirmak F., Demir G.G., Gokdeniz T., Gunes H.M., Cakal B., Guler E., Karaca I.O., Omaygen&#xe7; M.O., Y&#x131;lmaz F., Olgun F.E., et al. Changes in electrocardiographic P wave parameters after cryoballoon ablation and their association with atrial fibrillation recurrence. Ann. Noninvasive Electrocardiol. 2016;21:580&#x2013;587. doi: 10.1111/anec.12364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anec.12364</ArticleId><ArticleId IdType="pmc">PMC6931592</ArticleId><ArticleId IdType="pubmed">27018476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzeroni D., Parati G., Bini M. P-wave dispersion predicts atrial fibrillation following cardiac surgery. Int. J. Cardiol. 2016;203:131&#x2013;133. doi: 10.1016/j.ijcard.2015.10.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.10.143</ArticleId><ArticleId IdType="pubmed">26512825</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomaa M.M.M., Elsafty E.E.A., Gomaa H.M.M., Abdulrahim M.M., Eladawy A.H.H. Study of P wave dispersion in patients with paroxysmal atrial fibrillation and its role in the prediction of atrial fibrillation recurrence. Egypt. Heart J. 2024;76:80. doi: 10.1186/s43044-024-00503-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43044-024-00503-4</ArticleId><ArticleId IdType="pmc">PMC11211287</ArticleId><ArticleId IdType="pubmed">38935185</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi A., Takagi M., Katayama H., Yoshiyama T., Hayashi Y., Tatsumi H., Yoshiyama M. Diagnostic value of electrocardiographic P-wave characteristics in atrial fibrillation recurrence and tachycardia-induced cardiomyopathy after catheter ablation. Heart Vessels. 2018;33:1381&#x2013;1389. doi: 10.1007/s00380-018-1179-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-018-1179-4</ArticleId><ArticleId IdType="pubmed">29713820</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng T., Zhao Y., Ye Q., Zheng S., Meng F., Hu Q., Zhang H., Han J., Tian B., Zhu J., et al. Impact of pulmonary arterial systolic pressure on patients with mitral valve disease combined with atrial fibrillation. Front. Cardiovasc. Med. 2023;9:1047715. doi: 10.3389/fcvm.2022.1047715.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1047715</ArticleId><ArticleId IdType="pmc">PMC9868267</ArticleId><ArticleId IdType="pubmed">36698961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41010679</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Cardiovascular Effects of Inflammatory Bowel Disease Therapy with Biologics and Small Molecules: A Comprehensive Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6476</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14186476</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> &#x399;nflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is increasingly associated with cardiovascular (CV) complications, such as heart failure (HF), arrhythmias, and acute coronary syndromes (ACSs). As the therapeutic landscape of IBD evolves, with the introduction of newer biologics and small molecules, their CV safety warrants critical evaluation. The objective of this review is to provide an update on the current evidence of CV risks associated with IBD treatments. <b>Methods:</b> A comprehensive literature search from inception to April 2025 was conducted using PubMed and Medline to identify randomized controlled trials, observational studies, systematic reviews, as well as pharmacovigilance data reporting CV safety outcomes of biologic and small-molecule drugs approved for IBD. Additionally, analysis of the European Summary of Product Characteristics for each agent was also performed. <b>Results:</b> Anti-TNF agents, particularly infliximab, have been associated with increased reporting of HF and arrhythmias, particularly in patients with pre-existing cardiac disease. Ustekinumab and vedolizumab show consistently favorable CV safety profiles across trials and real-world studies. IL-23p19 inhibitors demonstrate low CV event rates overall, although signals for atrial fibrillation have emerged with risankizumab. Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators carry class-specific CV warnings, due to signals mainly on non-IBD populations, and require careful use in high-risk individuals. <b>Conclusions:</b> Although most IBD therapies are generally safe from a CV perspective, certain agents may pose risks in vulnerable patients. Individualized CV risk assessment and ongoing post-marketing surveillance are essential to guide therapeutic choices and ensure patient safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mastoridou</LastName><ForeName>Eleftheria M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0009-0000-3763-4064</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>1st Division of Internal Medicine, Department of Internal Medicine, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fousekis</LastName><ForeName>Fotios S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakellariou</LastName><ForeName>Xenofon M</ForeName><Initials>XM</Initials><Identifier Source="ORCID">0000-0002-1336-0211</Identifier><AffiliationInfo><Affiliation>2nd Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mpakogiannis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikas</LastName><ForeName>Dimitrios N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0002-8333-4879</Identifier><AffiliationInfo><Affiliation>1st Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalis</LastName><ForeName>Lampros K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0001-8834-4462</Identifier><AffiliationInfo><Affiliation>2nd Division of Cardiology, Department of Cardiology, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsanos</LastName><ForeName>Konstantinos H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milionis</LastName><ForeName>Haralampos</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3958-2266</Identifier><AffiliationInfo><Affiliation>1st Division of Internal Medicine, Department of Internal Medicine, University Hospital of Ioannina, 45500 Ioannina, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute coronary syndromes</Keyword><Keyword MajorTopicYN="N">arrhythmias</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">cardiovascular safety</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">small molecules</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41010679</ArticleId><ArticleId IdType="pmc">PMC12470398</ArticleId><ArticleId IdType="doi">10.3390/jcm14186476</ArticleId><ArticleId IdType="pii">jcm14186476</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogler G., Singh A., Kavanaugh A., Rubin D.T. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161:1118&#x2013;1132. doi: 10.1053/j.gastro.2021.07.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.07.042</ArticleId><ArticleId IdType="pmc">PMC8564770</ArticleId><ArticleId IdType="pubmed">34358489</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares C.A., Fiuza J.G., Rodrigues C.A.M., Craveiro N., Gil Pereira J., Sousa P.C.R.F., Martins D.C.P., Cancela E.M., dos Santos M.P.M. Inflammatory bowel disease and cardiac function: A systematic review of literature with meta-analysis. Ther. Adv. Gastroenterol. 2024;17:17562848241299534. doi: 10.1177/17562848241299534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562848241299534</ArticleId><ArticleId IdType="pmc">PMC11650564</ArticleId><ArticleId IdType="pubmed">39691207</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera P.A., Lasa J.S., Peretto G., Zuily S., Danese S., Peyrin-Biroulet L. Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs. Aliment. Pharmacol. Ther. 2023;57:1231&#x2013;1248. doi: 10.1111/apt.17509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.17509</ArticleId><ArticleId IdType="pubmed">37038269</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera P.A., Dignass A., Dubinsky M.C., Peretto G., Kotze P.G., Dotan I., Kobayashi T., Ghosh S., Magro F., Faria-Neto J.R., et al. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus. Dig. Liver Dis. 2024;56:1270&#x2013;1280. doi: 10.1016/j.dld.2024.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2024.03.010</ArticleId><ArticleId IdType="pubmed">38584033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinh P., Cross R.K. Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences. Gastroenterol. Hepatol. 2024;20:204&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11047149</ArticleId><ArticleId IdType="pubmed">38682122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha T., Zain Z., Bokhari S.F.H., Waheed S., Reza T., Eze-Odurukwe A., Patel M., Almadhoun M.K.I.K., Hussain A., Reyaz I. Navigating the Gut-Cardiac Axis: Understanding Cardiovascular Complications in Inflammatory Bowel Disease. Cureus. 2024;16:e55268. doi: 10.7759/cureus.55268.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.55268</ArticleId><ArticleId IdType="pmc">PMC10981543</ArticleId><ArticleId IdType="pubmed">38558708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunu D.-M., Timofte C.-E., Ciocoiu M., Floria M., Tarniceriu C.-C., Barboi O.-B., Tanase D.-M. Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol. Res. Pract. 2019;2019:3012509. doi: 10.1155/2019/3012509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/3012509</ArticleId><ArticleId IdType="pmc">PMC6348818</ArticleId><ArticleId IdType="pubmed">30733802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbiadini R., Buono A.D., Mastrorocco E., Solitano V., Repici A., Spinelli A., Condorelli G., Armuzzi A. Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: To the heart of the issue. Front. Cardiovasc. Med. 2023;10:1143293. doi: 10.3389/fcvm.2023.1143293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1143293</ArticleId><ArticleId IdType="pmc">PMC10227624</ArticleId><ArticleId IdType="pubmed">37260950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.N., Yao Y., Ju S.Y. Heart rate variability and inflammatory bowel disease in humans: A systematic review and meta-analysis. Medicine. 2020;99:e23430. doi: 10.1097/MD.0000000000023430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023430</ArticleId><ArticleId IdType="pmc">PMC7710256</ArticleId><ArticleId IdType="pubmed">33235125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P., Makharia G.K., Ahuja V., Dwivedi S.N., Deepak K.K. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. Dig. Dis. Sci. 2009;54:853&#x2013;861. doi: 10.1007/s10620-008-0424-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-008-0424-6</ArticleId><ArticleId IdType="pubmed">18712478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin D.T., Allegretti J.R., Pan&#xe9;s J., Shipitofsky N., Yarandi S.S., Huang K.-H.G., Germinaro M., Wilson R., Zhang H., Johanns J., et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405:33&#x2013;49. doi: 10.1016/S0140-6736(24)01927-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)01927-5</ArticleId><ArticleId IdType="pubmed">39706209</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwill M., Baillie S., Clough J., Pollok R., Poullis A., Patel K., Honap S. Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease-From Bench to Bedside. J. Clin. Med. 2025;14:1001. doi: 10.3390/jcm14031001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm14031001</ArticleId><ArticleId IdType="pmc">PMC11818495</ArticleId><ArticleId IdType="pubmed">39941671</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis E., Schreiber S., Panaccione R., Bossuyt P., Biedermann L., Colombel J.F., Parkes G., Peyrin-Biroulet L., D&#x2019;Haens G., Hisamatsu T., et al. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024;332:881&#x2013;897. doi: 10.1001/jama.2024.12414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.12414</ArticleId><ArticleId IdType="pmc">PMC11264075</ArticleId><ArticleId IdType="pubmed">39037800</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeire S., Rubin D.T., Peyrin-Biroulet L., Dubinsky M.C., Regueiro M., Irving P.M., Goetsch M., Lazin K., Gu G., Wu J., et al. Cardiovascular events observed among patients in the etrasimod clinical programme: An integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025;12:e001516. doi: 10.1136/bmjgast-2024-001516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgast-2024-001516</ArticleId><ArticleId IdType="pmc">PMC11748931</ArticleId><ArticleId IdType="pubmed">39778975</ArticleId></ArticleIdList></Reference><Reference><Citation>Filimon A.M., Negreanu L., Doca M., Ciobanu A., Preda C.M., Vinereanu D. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J. Gastroenterol. 2015;21:9688&#x2013;9692. doi: 10.3748/wjg.v21.i33.9688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i33.9688</ArticleId><ArticleId IdType="pmc">PMC4562952</ArticleId><ArticleId IdType="pubmed">26361415</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza R.F., Caetano M.A.F., Magalh&#xe3;es H.I.R., Castelucci P. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J. Gastroenterol. 2023;29:2733&#x2013;2746. doi: 10.3748/wjg.v29.i18.2733.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i18.2733</ArticleId><ArticleId IdType="pmc">PMC10237104</ArticleId><ArticleId IdType="pubmed">37274062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon H., Minozzi S., Kopylov U., Verstockt B., Chaparro M., Buskens C., Warusavitarne J., Agrawal M., Allocca M., Atreya R., et al. ECCO Guidelines on Therapeutics in Crohn&#x2019;s Disease: Medical Treatment. J. Crohns Colitis. 2024;18:1531&#x2013;1555. doi: 10.1093/ecco-jcc/jjae091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjae091</ArticleId><ArticleId IdType="pubmed">38877997</ArticleId></ArticleIdList></Reference><Reference><Citation>Raine T., Bonovas S., Burisch J., Kucharzik T., Adamina M., Annese V., Bachmann O., Bettenworth D., Chaparro M., Czuber-Dochan W., et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohns Colitis. 2022;16:2&#x2013;17. doi: 10.1093/ecco-jcc/jjab178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab178</ArticleId><ArticleId IdType="pubmed">34635919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemperly A., Casteele N.V. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin. Pharmacokinet. 2018;57:929&#x2013;942. doi: 10.1007/s40262-017-0627-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-017-0627-0</ArticleId><ArticleId IdType="pubmed">29330783</ArticleId></ArticleIdList></Reference><Reference><Citation>Juillerat P., Grueber M.M., Ruetsch R., Santi G., Vuill&#xe8;moz M., Michetti P. Positioning biologics in the treatment of IBD: A practical guide. Curr. Res. Pharmacol. Drug Discov. 2022;3:100104. doi: 10.1016/j.crphar.2022.100104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crphar.2022.100104</ArticleId><ArticleId IdType="pmc">PMC9092374</ArticleId><ArticleId IdType="pubmed">35570855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo T.G., Almeida L.R., Beraldo R.F., Marcondes M.B., Queir&#xf3;z D.A.R., da Silva D.L., Quera R., Baima J.P., Saad-Hossne R., Sassaki L.Y. Heart failure as an adverse effect of infliximab for Crohn&#x2019;s disease: A case report and review of the literature. World J. Clin. Cases. 2021;9:10382&#x2013;10391. doi: 10.12998/wjcc.v9.i33.10382.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i33.10382</ArticleId><ArticleId IdType="pmc">PMC8638044</ArticleId><ArticleId IdType="pubmed">34904114</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Infliximab&#x2014;Summary of Product Characteristics. 2025.  [(accessed on 17 April 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA  Adalimumab&#x2014;Summary of Product Characteristics. 2025.  [(accessed on 17 April 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA  Golimumab-Summary of Product Characteristics. 2024.  [(accessed on 17 April 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Cacciapaglia F., Navarini L., Menna P., Salvatorelli E., Minotti G., Afeltra A. Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmun. Rev. 2011;10:631&#x2013;635. doi: 10.1016/j.autrev.2011.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.04.014</ArticleId><ArticleId IdType="pubmed">21539939</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T., Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133&#x2013;3140.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe1;&#x161; L., Laz&#xfa;rov&#xe1; I., Pundov&#xe1; L., Oetterov&#xe1; M., Zakuciov&#xe1; M., Petr&#xe1;&#x161;ov&#xe1; D., Studen&#x10d;an M. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin. Rheumatol. 2013;32:61&#x2013;66. doi: 10.1007/s10067-012-2091-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-2091-4</ArticleId><ArticleId IdType="pubmed">23010850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon H.J., Cot T.R., Cuffe M.S., Kramer J.M., Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 2003;138:807&#x2013;811. doi: 10.7326/0003-4819-138-10-200305200-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-138-10-200305200-00008</ArticleId><ArticleId IdType="pubmed">12755552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatamnejad M.R., Karvandi M., Jodatfar F., Ebrahimi N., Shojaeian F., Ghavami S.B., Balaii H., Moeeni M., Rajabnia M., Shahrokh S., et al. Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. Front. Med. 2022;9:1008711. doi: 10.3389/fmed.2022.1008711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1008711</ArticleId><ArticleId IdType="pmc">PMC9853977</ArticleId><ArticleId IdType="pubmed">36687438</ArticleId></ArticleIdList></Reference><Reference><Citation>Orakzai A.A., Khan O.S., Sharif M.H., Raza S.S., Rashid M.U. S39 Heart Failure as an Adverse Outcome with the Use of Biologic Medications for Crohn&#x2019;s Colitis: A Pharmacovigilance Study. Am. J. Gastroenterol. 2023;118:S11. doi: 10.14309/01.ajg.0000995892.37484.ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/01.ajg.0000995892.37484.ab</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafyllou C., Nikolaou M., Ikonomidis I., Bamias G., Kouretas D., Andreadou I., Tsoumani M., Thymis J., Papaconstantinou I. Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. Diagnostics. 2021;11:993. doi: 10.3390/diagnostics11060993.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11060993</ArticleId><ArticleId IdType="pmc">PMC8227308</ArticleId><ArticleId IdType="pubmed">34070768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotyla P.J., Owczarek A., Rakoczy J., Lewicki M., Kucharz E.J., Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: Assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J. Rheumatol. 2012;39:701&#x2013;706. doi: 10.3899/jrheum.110751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110751</ArticleId><ArticleId IdType="pubmed">22337242</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.-J., Choi E.-K., Han K.-D., Park J., Moon I., Lee E., Choe W.-S., Lee S.-R., Cha M.-J., Lim W.-H., et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study. World J. Gastroenterol. 2019;25:2788&#x2013;2798. doi: 10.3748/wjg.v25.i22.2788.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i22.2788</ArticleId><ArticleId IdType="pmc">PMC6580358</ArticleId><ArticleId IdType="pubmed">31236001</ArticleId></ArticleIdList></Reference><Reference><Citation>George S.A., Calhoun P.J., Gourdie R.G., Smyth J.W., Poelzing S. TNF&#x3b1; Modulates Cardiac Conduction by Altering Electrical Coupling between Myocytes. Front. Physiol. 2017;8:334. doi: 10.3389/fphys.2017.00334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00334</ArticleId><ArticleId IdType="pmc">PMC5440594</ArticleId><ArticleId IdType="pubmed">28588504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofos S., Savoye G., Ramirez S., Bauer F., Lerebours E. Transient type III atrioventricular block after infliximab infusion in a fistulizing perianal Crohn&#x2019;s disease patient. Am. J. Gastroenterol. 2007;102:217&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278277</ArticleId></ArticleIdList></Reference><Reference><Citation>Senel S., Cobankara V., Taskoylu O., Guclu A., Evrengul H., Kaya M.G. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis. J. Investig. Med. 2011;59:1273&#x2013;1275. doi: 10.2310/JIM.0b013e3182330720.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/JIM.0b013e3182330720</ArticleId><ArticleId IdType="pubmed">21955979</ArticleId></ArticleIdList></Reference><Reference><Citation>Panteris V., Perdiou A., Tsirimpis V., Karamanolis D.G. Acute coronary syndrome after infliximab therapy in a patient with Crohn&#x2019;s disease. World J. Gastroenterol. 2006;12:6235&#x2013;6238. doi: 10.3748/wjg.v12.i38.6235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i38.6235</ArticleId><ArticleId IdType="pmc">PMC4088126</ArticleId><ArticleId IdType="pubmed">17036404</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedin M., Scheurich D., Reimold S.C., Reimold A.M. Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 2006;14:50&#x2013;52. doi: 10.1097/01.crd.0000178320.51474.ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.crd.0000178320.51474.ac</ArticleId><ArticleId IdType="pubmed">16371767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Cai J., Chen H., Feng Z., Yang G. Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis. J. Atheroscler. Thromb. 2024;31:1733&#x2013;1747. doi: 10.5551/jat.64767.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.64767</ArticleId><ArticleId IdType="pmc">PMC11620835</ArticleId><ArticleId IdType="pubmed">38866553</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P.M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905&#x2013;2912. doi: 10.1002/art.22809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22809</ArticleId><ArticleId IdType="pmc">PMC2435427</ArticleId><ArticleId IdType="pubmed">17763428</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanizza J., D&#x2019;amico F., Lusetti F., Fasulo E., Allocca M., Furfaro F., Zilli A., Parigi T.L., Radice S., Peyrin-Biroulet L., et al. The Role of IL-23 Inhibitors in Crohn&#x2019;s Disease. J. Clin. Med. 2023;13:224. doi: 10.3390/jcm13010224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13010224</ArticleId><ArticleId IdType="pmc">PMC10779938</ArticleId><ArticleId IdType="pubmed">38202231</ArticleId></ArticleIdList></Reference><Reference><Citation>Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R., Blank M.A., Johanns J., Gao L.-L., Miao Y., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn&#x2019;s Disease. N. Engl. J. Med. 2016;375:1946&#x2013;1960. doi: 10.1056/NEJMoa1602773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1602773</ArticleId><ArticleId IdType="pubmed">27959607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands B.E., Sandborn W.J., Panaccione R., O&#x2019;bRien C.D., Zhang H., Johanns J., Adedokun O.J., Li K., Peyrin-Biroulet L., Van Assche G., et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2019;381:1201&#x2013;1214. doi: 10.1056/NEJMoa1900750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1900750</ArticleId><ArticleId IdType="pubmed">31553833</ArticleId></ArticleIdList></Reference><Reference><Citation>Forss A., Clements M., Myrelid P., Strid H., S&#xf6;derman C., Wagner A., Andersson D., Hjelm F., The PROSE SWIBREG study group. Ol&#xe9;n O., et al. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn&#x2019;s Disease. Dig. Dis. Sci. 2023;68:65&#x2013;76. doi: 10.1007/s10620-022-07501-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-022-07501-z</ArticleId><ArticleId IdType="pmc">PMC9883312</ArticleId><ArticleId IdType="pubmed">35459973</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Stelara: EPAR&#x2014;Product Information. 2023.  [(accessed on 10 May 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Johnson A.M., Barsky M., Ahmed W., Zullow S., Galati J., Jairath V., Narula N., Peerani F., Click B.H., Coburn E.S., et al. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn&#x2019;s Disease: Results From the SUCCESS Consortium. Am. J. Gastroenterol. 2023;118:317&#x2013;328. doi: 10.14309/ajg.0000000000002047.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000002047</ArticleId><ArticleId IdType="pubmed">36191274</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparro M., Baston-Rey I., Fern&#xe1;ndez-Salgado E., Garc&#xed;a J.G., Ramos L., Palomares M.T.D.-L., Arg&#xfc;elles-Arias F., Flores E.I., Cabello M., Iturria S.R., et al. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn&#x2019;s Disease Patients: The SUSTAIN Study. Inflamm. Bowel Dis. 2022;28:1725&#x2013;1736. doi: 10.1093/ibd/izab357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab357</ArticleId><ArticleId IdType="pmc">PMC9629456</ArticleId><ArticleId IdType="pubmed">35166347</ArticleId></ArticleIdList></Reference><Reference><Citation>Teresa V.D., R&#xe1;ul O.M., Marisa I., Claudia H.d.G., Esteban F.-V., Luigi M., Mar M.-R.M., Lilyan K.C., Luisa D.C.P., &#xc1;ngel P.D., et al. Effectiveness and safety of ustekinumab in bio-na&#xef;ve Crohn&#x2019;s disease patients: A multicentre observational retrospective study. Ther. Adv. Gastroenterol. 2023;16:17562848231153560. doi: 10.1177/17562848231153560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562848231153560</ArticleId><ArticleId IdType="pmc">PMC9912551</ArticleId><ArticleId IdType="pubmed">36777363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.P., Desai R.J., Jin Y., Brill G., Ogdie A., Kim S.C. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatol. 2019;155:700&#x2013;707. doi: 10.1001/jamadermatol.2019.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2019.0001</ArticleId><ArticleId IdType="pmc">PMC6563547</ArticleId><ArticleId IdType="pubmed">30916734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S., Feagan B.G., Ott E., Gasink C., Godwin B., Marano C., Miao Y., Ma T., Loftus E.V., Sandborn W.J., et al. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn&#x2019;s Disease and 4 Years in Ulcerative Colitis. J. Crohn&#x2019;s Colitis. 2024;18:1091&#x2013;1101. doi: 10.1093/ecco-jcc/jjae013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjae013</ArticleId><ArticleId IdType="pmc">PMC11302965</ArticleId><ArticleId IdType="pubmed">38310565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan E.S.-Y., Polpichai N., Yang H.Y., Tran V.N., Hsieh R., Mukhtar R., Patel J. COMPARATIVE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH VEDOLIZUMAB VS USTEKINUMAB IN OLDER ADULTS WITH INFLAMMATORY BOWEL DISEASE: A PROPENSITY-MATCHED COHORT ANALYSIS. Inflamm. Bowel Dis. 2025;31((Suppl. S1)):S40&#x2013;S41. doi: 10.1093/ibd/izae282.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izae282.091</ArticleId></ArticleIdList></Reference><Reference><Citation>Poizeau F., Nowak E., Kerbrat S., Le Nautout B., Droitcourt C., Drici M.-D., Sbidian E., Guillot B., Bachelez H., Ait-Oufella H., et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020;156:1208&#x2013;1215. doi: 10.1001/jamadermatol.2020.2977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamadermatol.2020.2977</ArticleId><ArticleId IdType="pmc">PMC7489429</ArticleId><ArticleId IdType="pubmed">32902568</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng M.W.L., Bowman E.P., McElwee J.J., Smyth M.J., Casanova J.-L., Cooper A.M., Cua D.J. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 2015;21:719&#x2013;729. doi: 10.1038/nm.3895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3895</ArticleId><ArticleId IdType="pubmed">26121196</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;hAens G., Dubinsky M., Kobayashi T., Irving P.M., Howaldt S., Pokrotnieks J., Krueger K., Laskowski J., Li X., Lissoos T., et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2023;388:2444&#x2013;2455. doi: 10.1056/NEJMoa2207940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2207940</ArticleId><ArticleId IdType="pubmed">37379135</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;HAens G., Panaccione R., Baert F., Bossuyt P., Colombel J.-F., Danese S., Dubinsky M., Feagan B.G., Hisamatsu T., Lim A., et al. Risankizumab as induction therapy for Crohn&#x2019;s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015&#x2013;2030. doi: 10.1016/S0140-6736(22)00467-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00467-6</ArticleId><ArticleId IdType="pubmed">35644154</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Tremfya (guselkumab) Summary of Product Characteristics. 2024.  [(accessed on 4 June 2025)].  Available online:  https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya.</Citation></Reference><Reference><Citation>EMA  Omvoh (mirikizumab) Summary of Product Characteristics. 2025.  [(accessed on 4 June 2025)].  Available online:  https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh.</Citation></Reference><Reference><Citation>EMA  Skyrizi (risankizumab) Summary of Product Characteristics. 2025.  [(accessed on 4 June 2025)].  Available online:  https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration  . Multi-Discipline Review and Evaluation of BLA 761105 (Skyrizi, Risankizumab-Rzaa) AbbVie Inc.; North Chicago, IL, USA: 2019.  [(accessed on 15 July 2025)].  Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761105Orig1s000MultidisciplineR.pdf.</Citation></Reference><Reference><Citation>Al-Yafeai Z., Sondhi M., Vadlamudi K., Vyas R., Nadeem D., Alawadi M., Carvajal-Gonz&#xe1;lez A., Ghoweba M., Ananthaneni A. Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS) Int. J. Cardiol. 2024;402:131819. doi: 10.1016/j.ijcard.2024.131819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2024.131819</ArticleId><ArticleId IdType="pubmed">38301830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon K.B., Lebwohl M., Papp K.A., Bachelez H., Wu J.J., Langley R.G., Blauvelt A., Kaplan B., Shah M., Zhao Y., et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 2022;186:466&#x2013;475. doi: 10.1111/bjd.20818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.20818</ArticleId><ArticleId IdType="pmc">PMC9298814</ArticleId><ArticleId IdType="pubmed">34652810</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubatan J., Keyashian K., Rubin S.J.S., Wang J., Buckman C.A., Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin. Exp. Gastroenterol. 2021;14:333&#x2013;342. doi: 10.2147/CEG.S293272.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEG.S293272</ArticleId><ArticleId IdType="pmc">PMC8402953</ArticleId><ArticleId IdType="pubmed">34466013</ArticleId></ArticleIdList></Reference><Reference><Citation>Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.-F., Sandborn W.J., Van Assche G., Axler J., Kim H.-J., Danese S., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013;369:699&#x2013;710. doi: 10.1056/NEJMoa1215734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215734</ArticleId><ArticleId IdType="pubmed">23964932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn W.J., Feagan B.G., Rutgeerts P., Hanauer S., Colombel J.-F., Sands B.E., Lukas M., Fedorak R.N., Lee S., Bressler B., et al. Vedolizumab as induction and maintenance therapy for Crohn&#x2019;s disease. N. Engl. J. Med. 2013;369:711&#x2013;721. doi: 10.1056/NEJMoa1215739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215739</ArticleId><ArticleId IdType="pubmed">23964933</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q., Zhang J., Tang W., Zhou M., Zhang X., Yuan P. Data mining and analysis of adverse events of Vedolizumab based on the FAERS database. Sci. Rep. 2025;15:278. doi: 10.1038/s41598-024-75421-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-75421-1</ArticleId><ArticleId IdType="pmc">PMC11696444</ArticleId><ArticleId IdType="pubmed">39747183</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulai P.S., Singh S., Jiang X., Peerani F., Narula N., Chaudrey K., Whitehead D., Hudesman D., Lukin D., Swaminath A., et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn&#x2019;s Disease: Results From the US VICTORY Consortium. Am. J. Gastroenterol. 2016;111:1147&#x2013;1155. doi: 10.1038/ajg.2016.236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.236</ArticleId><ArticleId IdType="pubmed">27296941</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Vedolizumab (Entyvio)&#x2014;Summary of Product Characteristics. 2025.  [(accessed on 18 May 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Loftus E.V., Feagan B.G., Panaccione R., Colombel J., Sandborn W.J., Sands B.E., Danese S., D&#x2019;hAens G., Rubin D.T., Shafran I., et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment. Pharmacol. Ther. 2020;52:1353&#x2013;1365. doi: 10.1111/apt.16060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16060</ArticleId><ArticleId IdType="pmc">PMC7540482</ArticleId><ArticleId IdType="pubmed">32876349</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparro M., Garre A., Ricart E., Iborra M., Mesonero F., Vera I., Riestra S., Garc&#xed;a-S&#xe1;nchez V., De Castro M.L., Martin-Cardona A., et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: Results from the ENEIDA registry. Aliment. Pharmacol. Ther. 2018;48:839&#x2013;851. doi: 10.1111/apt.14930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14930</ArticleId><ArticleId IdType="pubmed">30281832</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross R.K., Chiorean M., Vekeman F., Xiao Y., Wu E., Chao J., Wang A.W., Qian J. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS ONE. 2019;14:e0225572. doi: 10.1371/journal.pone.0225572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0225572</ArticleId><ArticleId IdType="pmc">PMC6892509</ArticleId><ArticleId IdType="pubmed">31800627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante M., Panaccione R., Baert F., Bossuyt P., Colombel J.-F., Danese S., Dubinsky M., Feagan B.G., Hisamatsu T., Lim A., et al. Risankizumab as maintenance therapy for moderately to severely active Crohn&#x2019;s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399:2031&#x2013;2046. doi: 10.1016/S0140-6736(22)00466-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00466-4</ArticleId><ArticleId IdType="pubmed">35644155</ArticleId></ArticleIdList></Reference><Reference><Citation>E Sands B., D&#x2019;hAens G., Clemow D.B., Irving P.M., Johns J.T., Gibble T.H., Abreu M.T., Lee S., Hisamatsu T., Kobayashi T., et al. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm. Bowel Dis. 2024;30:2245&#x2013;2258. doi: 10.1093/ibd/izae024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izae024</ArticleId><ArticleId IdType="pmc">PMC11630283</ArticleId><ArticleId IdType="pubmed">38459910</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu E., Aslam N., Nigam G., Limdi J.K. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context. 2022;11 doi: 10.7573/dic.2021-11-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.2021-11-4</ArticleId><ArticleId IdType="pmc">PMC9007061</ArticleId><ArticleId IdType="pubmed">35462642</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Napoli R., Richez C., Scavone C., Singier A., Demourgues M., Mascolo A., Capuano A., Salvo F. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database. Drug Saf. 2025;48:955. doi: 10.1007/s40264-025-01552-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-025-01552-7</ArticleId><ArticleId IdType="pmc">PMC12259764</ArticleId><ArticleId IdType="pubmed">40261507</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Xeljanz: Summary of Product Characteristics. 2025.  [(accessed on 12 June 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA  Rinvoq (upadacitinib)&#x2014;Summary of Product Characteristics. EMA. 2025.  [(accessed on 15 June 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA  Summary of Product Characteristics. EMA. 2025.  [(accessed on 15 June 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Khataniar H., Sehgal P., Tabaku F., Kochhar G., Desai A. S25 Cardiovascular Risk in Patients With Inflammatory Bowel Disease on Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors: A Real-World Study in a Cardiovascular Risk-Enriched Population. Am. J. Gastroenterol. 2024;119:S8. doi: 10.14309/01.ajg.0001082632.56121.0f.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/01.ajg.0001082632.56121.0f</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn W.J., Su C., Sands B.E., D&#x2019;hAens G.R., Vermeire S., Schreiber S., Danese S., Feagan B.G., Reinisch W., Niezychowski W., et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017;376:1723&#x2013;1736. doi: 10.1056/NEJMoa1606910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606910</ArticleId><ArticleId IdType="pubmed">28467869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ytterberg S.R., Bhatt D.L., Mikuls T.R., Koch G.G., Fleischmann R., Rivas J.L., Germino R., Menon S., Sun Y., Wang C., et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N. Engl. J. Med. 2022;386:316&#x2013;326. doi: 10.1056/NEJMoa2109927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109927</ArticleId><ArticleId IdType="pubmed">35081280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., An T., Zhao Y., Shi X., Wang B., Zhang Q. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: A systematic review and network meta-analysis. Ann. Med. 2025;57:2455536. doi: 10.1080/07853890.2025.2455536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2025.2455536</ArticleId><ArticleId IdType="pmc">PMC11755742</ArticleId><ArticleId IdType="pubmed">39838595</ArticleId></ArticleIdList></Reference><Reference><Citation>Choden T., Cohen N.A., Rubin D.T. Sphingosine-1 Phosphate Receptor Modulators: The Next Wave of Oral Therapies in Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2022;18:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666818</ArticleId><ArticleId IdType="pubmed">36397756</ArticleId></ArticleIdList></Reference><Reference><Citation>Armuzzi A., Cross R.K., Lichtenstein G.R., Hou J., Deepak P., Regueiro M., Wolf D.C., Akukwe L., Ahmad H.A., Jain A., et al. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. Clin. Gastroenterol. Hepatol. 2024;22:1067&#x2013;1076.e3. doi: 10.1016/j.cgh.2023.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2023.11.018</ArticleId><ArticleId IdType="pubmed">38040274</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn W.J., Vermeire S., Peyrin-Biroulet L., Dubinsky M.C., Panes J., Yarur A., Ritter T., Baert F., Schreiber S., Sloan S., et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159&#x2013;1171. doi: 10.1016/S0140-6736(23)00061-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00061-2</ArticleId><ArticleId IdType="pubmed">36871574</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA  Zeposia (ozanimod) Summary of Product Characteristics. 2025.  [(accessed on 14 June 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/zeposia-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>EMA  Velsipity (etrasimod) Summary of Product Characteristics. 2024.  [(accessed on 14 June 2025)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Cohen N.A., Choi D., Choden T., Cleveland N.K., Cohen R.D., Rubin D.T. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin. Gastroenterol. Hepatol. 2023;21:2407&#x2013;2409.e2. doi: 10.1016/j.cgh.2022.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.03.035</ArticleId><ArticleId IdType="pmc">PMC11009929</ArticleId><ArticleId IdType="pubmed">35381385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn W.J., Feagan B.G., D&#x2019;hAens G., Wolf D.C., Jovanovic I., Hanauer S.B., Ghosh S., Petersen A., Hua S.Y., Lee J.H., et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2021;385:1280&#x2013;1291. doi: 10.1056/NEJMoa2033617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033617</ArticleId><ArticleId IdType="pubmed">34587385</ArticleId></ArticleIdList></Reference><Reference><Citation>Haudek S.B., Taffet G.E., Schneider M.D., Mann D.L. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J. Clin. Investig. 2007;117:2692&#x2013;2701. doi: 10.1172/JCI29134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI29134</ArticleId><ArticleId IdType="pmc">PMC1937497</ArticleId><ArticleId IdType="pubmed">17694177</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi Y., McTiernan C.F., Frye C.B., McGowan B.S., Chan T.O., Feldman A.M. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation. 2004;109:1892&#x2013;1897. doi: 10.1161/01.CIR.0000124227.00670.AB.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000124227.00670.AB</ArticleId><ArticleId IdType="pubmed">15051641</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzentales-Simpson M., Pang Y.C.F., Zhang A., Sousa J.A., Sly L.M. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front. Cell Dev. Biol. 2021;9:612830. doi: 10.3389/fcell.2021.612830.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.612830</ArticleId><ArticleId IdType="pmc">PMC7887288</ArticleId><ArticleId IdType="pubmed">33614645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Zhao P., Gao Y., Zhang F., Yuan X., Jiao Y., Gong K. The Effects of Anti-IL-23p19 Therapy on Atherosclerosis Development in ApoE. J. Interf. Cytokine Res. 2019;39:564&#x2013;571. doi: 10.1089/jir.2019.0050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2019.0050</ArticleId><ArticleId IdType="pubmed">31264927</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldini C., Moriconi F.R., Galimberti S., Libby P., De Caterina R. The JAK-STAT pathway: An emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur. Hear. J. 2021;42:4389&#x2013;4400. doi: 10.1093/eurheartj/ehab447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab447</ArticleId><ArticleId IdType="pmc">PMC8572559</ArticleId><ArticleId IdType="pubmed">34343257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasa J.S., Olivera P.A., Bonovas S., Danese S., Peyrin-Biroulet L. Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Drug Saf. 2021;44:645&#x2013;660. doi: 10.1007/s40264-021-01057-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01057-z</ArticleId><ArticleId IdType="pubmed">33666900</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaldaferri F., Gerardi V., Mangiola F., Lopetuso L.R., Pizzoferrato M., Petito V., Papa A., Stojanovic J., Poscia A., Cammarota G., et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World J. Gastroenterol. 2016;22:5505&#x2013;5511. doi: 10.3748/wjg.v22.i24.5505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i24.5505</ArticleId><ArticleId IdType="pmc">PMC4917610</ArticleId><ArticleId IdType="pubmed">27350728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon A., Robertson K., Yung A., Que M., Randall H., Wellalagodage D., Cox T., Robertson D., Chi C., Sun J. Efficacy of Probiotics in Patients of Cardiovascular Disease Risk: A Systematic Review and Meta-analysis. Curr. Hypertens. Rep. 2020;22:74. doi: 10.1007/s11906-020-01080-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-020-01080-y</ArticleId><ArticleId IdType="pubmed">32860083</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>